Blog

May 03, 2023

FDA drug review delays scrutinized by Sen. Cassidy

By John Wilkerson June 7, 2023 WASHINGTON — Sen. Bill Cassidy (R-La.) is looking

By John Wilkerson June 7, 2023

WASHINGTON — Sen. Bill Cassidy (R-La.) is looking into ways to speed up the Food and Drug Administration's process for reviewing new drugs.

"We’re at the reallllly early stages, like ‘can we talk about it?’ sort of thing," the ranking Senate health committee Republican said about his potential interest in putting a stop to the FDA's tactic for extending drug review deadlines.

advertisement

At issue are the product review deadlines that the FDA must meet in return for receiving industry user fees. The industries that the FDA regulates fund more than 45% of the agency's budget.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

Washington Correspondent

John Wilkerson is a Washington correspondent for STAT who writes about the politics of health care.

biotechnolgy

drug development

FDA

pharmaceuticals

This name will appear with your comment

There was an error saving your display name. Please check and try again.